Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine

British Journal of Clinical Pharmacology

Volumn 67, Issue 2, 2009, Pages 209-215

  Braun, Marina ^a   Cawello, Willi ^a   Boekens, Hilmar ^a   Horstmann, Rolf ^a  

^a Schwarz Pharma AG   (Germany)

Author keywords

Domperidone; Dopamine agonist; Drug drug interaction; Pharmacokinetics; Rotigotine transdermal patch; Safety

Indexed keywords

DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; ROTIGOTINE;

ADULT; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; MALE; MORNING DOSAGE; NAUSEA; NORMAL HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESS LEGS SYNDROME; STEADY STATE; SYNCOPE;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; CROSS-OVER STUDIES; DOMPERIDONE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; TETRAHYDRONAPHTHALENES; THIOPHENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 61349192144     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03334.x     Document Type: Article

References (24)

1. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 2005 65 (Suppl. 1 S3 5.
2. Pfeiffer RF. A promising new technology for Parkinson's disease. Neurology 2005 65 (Suppl. 1 S6 10.
3. Schwarz Pharma. Neupro® (Rotigotine Transdermal System). Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/neupro/H-626-PI-en.pdf (last accessed 5 November 2008).
4. Poewe W, Leussi F. Clinical studies with transdermal rotigotine in early Parkinson's disease. Neurology 2005 65 (Suppl. 1 S11 4.
5. Reynolds NA, Wellington K, Easthope SE. Rotigotine: in Parkinson's disease. CNS Drugs 2005 19 : 973 81.
6. Hansen K, Braun M, Horstmann R. Low drug-drug interaction potential of rotigotine. J Clin Pharmacol 2005 45 : 1091.
7. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007 68 : 272 6.
8. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007 6 : 513 20.
9. Oertel WH, Beneš H, García-Borreguero D, Geisler P, Högl B, Saletu B, Trenkwalder C, Sommerville KW, Schollmayer E, Kohnen R, Stiasny-Kolster K. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008 9 : 228 39.
10. Trenkwalder C, Beneš H, Poewe W, Oertel WH, García- Borreguero D, de Weerd AW, Ferini-Strambi L, Montagna P, Odin P, Stiasny-Kolster K, Högl B, Chaudhuri KR, Partinen M, Schollmayer E, Kohnen R. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008 7 : 595 604.
11. 2-receptor antagonist. Ann Pharmacother 1999 33 : 429 40.
12. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 1982 24 : 360 400.
13. Parkes JD. Domperidone and Parkinson's disease. Clin Neuropharmacol 1986 9 : 517 32.
14. Meuldermans W, Hurkmans R, Swysen E, Hendrickx J, Michiels M, Lauwers W, Heykants J. On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Pharmacokinet 1981 6 : 49 60.
15. Ward BA, Morocho A, Kandil A, Galinsky RE, Flockhart DA, Desta Z. Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol 2004 58 : 277 87.
16. Janssen-Cilag. Motilium® domperidone. Product information. Available at http://www.janssen-cilag.com.au/product/detail.jhtml?itemname=motilium (last accessed 4 November 2008).
17. 2-receptor agonist. Br J Clin Pharmacol 1991 32 : 483 8.
18. Bogaerts M, Braems M, Martens C. Domperidone in the prevention of L-dopa induced nausea. Postgrad Med J 1979 55 (Suppl. 1 51 2.
19. Corsini GU, Del Zompo M, Gessa GL, Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet 1979 1 : 954 6.
20. Langdon N, Malcolm PN, Parkes JD. Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease. Clin Neuropharmacol 1986 5 : 440 7.
21. Agid Y, Pollak P, Bonnet AM, Signoret JL, Lhermitte F. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease. Lancet 1979 1 : 570 2.
22. Quinn N, Illas A, Lhermitte F, Agid Y. Bromocriptine and domperidone in the treatment of Parkinson disease. Neurology 1981 31 : 662 7.
23. Hughes AJ, Bishop S, Kleedorfer B, Turjanski N, Fernandez W, Lees AJ, Stern GM. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993 8 : 165 70.
24. Jansen PAF, Herings RMC, Samson MM, De Vreede PL, Schuurmans-Daemen LMPJ, Hovestadt A, Verhaar HJJ, Van Laar T. Quick titration of pergolide in cotreatment with domperidone is safe and effective. Clin Neuropharmacol 2001 24 : 177 80.